Scholar Rock, LLC
http://www.scholarrock.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Scholar Rock, LLC
Scholar Rock Sees Phase III Path For SMA Drug
While the drug may be well-positioned for registrational development, some important caveats remain after mixed data in Phase II study cohorts.
Lung Cancer Failure Isn't The End For Merck KGaA And GSK's Bintrafusp
Key cancer asset is still looking for a Phase III validation after failing to outperform Keytruda in challenging frontline NSCLC setting.
The SMA Market: Assessing The Unknowns
The introductions of Spinraza and Zolgensma in SMA offer new insights into how to address neurodegenerative diseases. But more real world evidence is needed.
Finance Watch: Investors Bet On Hope As Four Early-Stage Companies Launch US IPOs
Public Company Edition: Of five drug developers expected to go public, four have preclinical or early clinical candidates, while the one that could not find a market for its IPO is in Phase III. Also, Biohaven, Zymeworks and Kura raise $100m or more in follow-on offerings.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
-
Large Molecule
- Other Names / Subsidiaries
-
- Scholar Rock, Inc.